The Chief Officer Financial Services has
approved the request from Labcorp Drug Development for business
rates relief at £335,000 over a three year period from
FY21/22 and the rates relief be released incrementally over 3 years
as follows: 40% in FY 2021/22 (£134,000), 40% in 2022/23
(£134,000) and 20% in 2023/24 (£67,000).